Letizia Bazzola

Learn More
BACKGROUND The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response. PATIENTS AND METHODS This single institution study comprised 120 oestrogen receptor (ER)-positive(More)
DNA repair is a key determinant in the cellular response to therapy and tumor repair status could play an important role in tailoring patient therapy. Our goal was to evaluate the mRNA of 13 genes involved in different DNA repair pathways (base excision, nucleotide excision, homologous recombination, and Fanconi anemia) in paraffin embedded samples of(More)
PURPOSE To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC). METHODS Thirteen oestrogen receptor-positive, postmenopausal, T2-4, N0-1 BC patients received the LCS combination for 6 months. In these patients we examined the pharmacokinetics of(More)
Purpose Considering the clear emerging role of the DNA repair and the cell cycle checkpoints as predictive, prognostic and therapeutic targets in cancer there is a need to better characterized human tumours to define subsets of patients that would benefit of a particular treatment modality. The aim of the present work is to characterize molecularly a cohort(More)
  • 1